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BACKGROUND: Aetiology of acute myeloid leukaemia (AML) is not well understood, perhaps because of its distinct subtypes.
High-dose ionising radiation is a known risk factor, but less is known about risk from low-dose exposure such as from diagnostic
radiography.
METHODS: Subjects were 412 matched case-control pairs. Ten-year subject histories of diagnostic radiography were based on
interview and medical records.
RESULTS:There was no convincing association between AML risk and ionising radiation exposure from diagnostic imaging procedures,
either for AML overall or for any AML subtype.
CONCLUSION: The association between diagnostic radiography and AML risk remains uncertain.
British Journal of Cancer (2011) 104, 1482–1486. doi:10.1038/bjc.2011.114 www.bjcancer.com
& 2011 Cancer Research UK
Keywords: acute myeloid leukaemia; case-control study; ionising radiation; radiography; diagnostic imaging
                                     
Aetiology of acute myeloid leukaemia (AML) is not well under-
stood, perhaps related to the fact that AML consists of
morphologically and genetically distinct subtypes. High-dose
ionising radiation is one of the known causes (Darby et al, 1987;
Preston et al, 1987), but less is known about risk from lower-dose
exposures, such as those received from diagnostic procedures.
The French–American–British (FAB) classification in use
at the time of our study divided AML into seven subtypes based
on morphological and cytochemical criteria (Bennett et al, 1976,
1985a,b). It seems plausible that specific exposures may correlate
with specific mutations in either stem or progenitor white blood
cells due to their vulnerability to particular carcinogens at different
stages of cellular growth and differentiation (Sandler et al, 1993).
The resulting phenotypic changes that constitute the different FAB
subtypes may also have unique risk factor profiles.
We report results from a large, population-based case-control
study of AML in Los Angeles County, California in which data on
diagnostic imaging procedures were collected from both interview
and medical records. Because we were able to determine FAB
subtype on almost 90% of cases, it was feasible to evaluate whether
AML risk from diagnostic radiography may be specific to certain
AML subtypes.
MATERIALS AND METHODS
The study protocol was approved by the University of Southern
California (USC) Institutional Review Board. Study design
and methodology have been previously described (Pogoda et al,
2002). New cases of adult-onset AML (ICDO codes 9861, 9864,
9866, 9867, and 9891) diagnosed in Los Angeles County from
January 1987 through June 1994 were identified by the USC Cancer
Surveillance Program (CSP), a population-based SEER cancer
registry. Other inclusion criteria included age between 30 and 69
years, the ability to speak English or Spanish, and U.S. residence
during the previous 15 years. Neighbourhood controls were
matched to cases by birth year (±5 years), ethnicity, and sex
according to a previously established protocol (Preston-Martin
et al, 1980).
Using the FAB classification scheme that was standard at the
time the study was conducted, cases were FAB-subtyped by review
of pathology reports (96%) or slides (4%) by one of us, an
experienced hematopathologist (PWN). For cases with FAB
subtype not specified on the pathology report or for whom
diagnostic information was otherwise incomplete, available
peripheral blood and bone marrow slides were reviewed to verify
the original AML diagnosis and to establish the FAB subtype.
Interviews were conducted from 1987 to 1997. Specific details of
procedures used to ascertain histories of diagnostic radiography
and to estimate dose have been published previously (Preston-
Martin and Pogoda, 2003). Respondents were systematically
queried on a specific list of imaging procedures and were also
asked to provide contact information for all providers they saw in
the 10 years before diagnosis, whether or not the provider ordered
or delivered diagnostic imaging procedures; these providers were
asked to provide details on all diagnostic imaging procedures
undergone by the subject during the 10 years of interest. Providers
were also asked for names of any other providers who had treated
the patient, and these additional providers were also contacted
and asked to provide the same information. A comparison of
exposure data from personal interviews vs medical records has
been published previously (Pogoda and Preston-Martin, 2002).
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procedure was accomplished by literature review and radiology
expert consultation (Preston-Martin and Pogoda, 2003). In brief,
we searched the literature for estimates of radiation dose to the
active red bone marrow for each procedure reported by our
respondents and used procedure-specific medians for our analysis.
For procedures for which we were unable to find literature-based
estimates, we consulted with radiologists to arrive at reasonable
estimates to use for analysis. We used the conversion equation
1Gy¼100 rad to convert all estimates to mGy.
Radiographic exposure was analysed as number of frequently
reported procedures (per medical records) and as total dose (mGy)
received. Categorical analyses were done using logistic regression
conditioned on matched pairs (Breslow and Day, 1980) and
adjusted for socioeconomic status (SES) (Hollingshead, 1957); cut
points were chosen a priori. Trend tests and multivariable analyses
of dose by age at exposure were done using continuous exposure
variables in logistic models. Population attributable risk (PAR) was
calculated using the continuous exposure variable (Bruzzi et al,
1985). As the PAR is a monotonic transformation of the risk
coefficient, its confidence interval (CI) was derived directly from
the risk coefficient likelihood-based CI. Primary analyses excluded
matched pairs in which the case or control had missing exposure
data and was limited to exposure in the 2–10 years before
diagnosis. A secondary analysis retained pairs with missing data
and used the missing indicator method (Huberman and Langholz,
1999). Analyses were done using SAS v9 (SAS Institute, Inc., Cary,
NC, USA) and Epicure v2.11 (Hirosoft International Corp., Seattle,
WA, USA). Tests were two-sided with 0.05 significance levels.
RESULTS
The CSP identified 725 cases of AML diagnosed January 1987 to
June 1994 who met inclusion criteria. Of these, 188 (26%) were
unavailable for interview with no available proxy, 31 (4%) were not
contacted as advised by their physicians, and 20 (3%) were lost to
follow-up. Therefore, 67% (486 out of 725) of eligible cases were
invited and 412 agreed to participate, or 57% (412 out of 725) of
those originally identified (85% (412 out of 486) of those
contacted. Proxies were used for 49% (201 out of 412) of cases.
Median length of time from AML diagnosis to interview was
7 months for personal and 14 months for proxy interviews. Median
number of months between case and control interview was 8.
Distributions for demographic variables and FAB subtype are
shown in Table 1. FAB subtype for proxy-interviewed cases was
more likely to be M0, M5, or missing than for those personally
interviewed. Cases and controls were similar on age and sex.
Despite matching by neighbourhood of residence, cases were
somewhat more likely to be Latino and to have lower SES. Of 51
cases (12%) with unknown FAB subtypes, most (82%) were due to
inadequate pathology materials being available. FAB subtypes of
Table 1 Distribution of study subjects by sex, age, ethnicity, SES, and
FAB subtype
Characteristic # Cases (%) # Controls (%)
Sex
Male 234 (57) 234 (57)
Female 178 (43) 178 (43)
Age (years)
25–39 57 (14) 57 (14)
40–49 67 (16) 74 (18)
50–59 109 (26) 104 (25)
60–75 179 (43) 177 (43)
Ethnicity
Non-Hispanic white 306 (74) 334 (81)
Hispanic 65 (16) 45 (11)
African American 37 (9) 31 (8)
Other 4 (1) 2 (0.5)
SES
a
Low 217 (53) 193 (47)
High 195 (47) 218 (53)
Unknown 0 (0) 1 (0.002)
FAB Subtype
M0 7 (2)
b
M1 70 (19)
M2 116 (32)
M3 34 (9)
M4 89 (25)
M4E 4 (1)
M5 17 (5)
M5a 3 (1)
M5b 6 (2)
Other
c 15 (4)
Unknown 51
Abbreviations: FAB¼French–American–British; RAEB¼refractory anaemia with
excess blasts; RAEB-T¼refractory anaemia with excess blasts in transformation;
SES¼socioeconomic status.
aBased on education and occupation according to
the Hollingshead Social Index (Hollingshead, 1957): low451, highp51.
bPercentages¼% of cases with non-missing FAB.
cIncludes RAEB (n¼4) and
RAEB-T (n¼11).
Table 2 Most frequently recorded diagnostic imaging procedures in
medical records
Procedure
Estimated
dose
a
(mGy)
# Subjects
with exam
recorded
(n¼716)
b
Total #
exams
recorded
Avg # exams
per subject
among those
with exam
Nuclear med scan,
high dose
c
15.83 47 60 1.3
GI tract CT 14.56 13 20 1.5
Coronary angiogram 12.67 28 41 1.5
GI series
d 5.05 107 158 1.5
Spine CT 4.13 20 33 1.7
Head/neck CT scan 3.00 35 55 1.6
KUB 2.14 51 61 1.2
GI tract x-ray 1.54 34 51 1.5
Spine x-ray 1.41 140 226 1.6
Hip/pelvis x-ray 0.57 42 68 1.6
Rib/sternum x-ray 0.49 26 39 1.5
Fluoroscopy, extremity 0.39 13 18 1.4
Shoulder x-ray 0.37 36 46 1.3
Nuclear med scan,
low dose
e
0.36 23 28 1.2
Head/neck x-ray 0.16 43 59 1.4
Mammogram 0.07 112 253 2.3
Chest x-ray 0.05 331 987 3.0
Extremity x-ray 0.00 158 400 2.5
Abdominal ultrasound 0.00 25 30 1.2
Hip/pelvis ultrasound 0.00 20 32 1.6
Hepatobiliary ultrasound 0.00 17 20 1.2
Abbreviations: Avg¼average; CT¼computed tomography; GI¼gastrointestinal
tract; KUB¼kidneys/ureters/bladder.
aDose to active bone marrow, equal to the
median dose among all procedures in the given category. In contrast, procedure-
specific dose estimates were used for analysis. For reference purposes, the average
annual background exposure in the US is 3mGy (Board on Radiation Effects
Research, 2006).
bOf 824 study participants, 38 case-control pairs were excluded due
to prior radiation treatment of either the case or control (or both), and an additional
18 pairs were excluded due to prior chemotherapy.
cAt least 2mGy (based on
specific scan performed).
dIncludes both upper and lower GI; for analysis, doses for
upper and lower GI were estimated separately.
eRange¼0.0001–0.72mGy (based
on specific scan performed).
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unknown.
Reasons for case-control pair exclusion in analyses were case
diagnosis of refractory anaemia with excess blasts (RAEB) or in
transformation (RAEB-T), also known as myelodysplastic syndrome
(n¼15), prior radiation therapy (n¼38), and prior chemotherapy
(n¼18) Also, 64 pairs were excluded from analysis of medical record
data because of data unavailability. Therefore, 344 matched pairs (83%
of pairs interviewed) were included in analysis of interview data and
279 pairs (68% of pairs interviewed) in analysis of medical record data.
Among those included, the average number of health care providers
identified in interviews was similar for cases and controls (4.0 and 3.7,
respectively), as was the average number of additional providers
identified by contacted providers (2.0 for cases and 1.4 for controls).
The diagnostic imaging procedures most frequently recorded in
subjects’ medical records, used in the ‘number of procedures’
analysis, are shown in Table 2. The most common as well as the
lowest-dose procedure was chest x-ray, with nearly 50% of all
respondents having had at least one during the period of interest,
whereas nuclear medicine scan had the highest estimated dose.
A natural cut point in the distribution of dose was 1 mGy, and this
was used to discriminate between ‘low-dose’ and ‘high-dose’
procedures in analyses.
Table 3 shows risk estimates for total number of high- and low-
dose frequently reported diagnostic imaging procedures. For
subtype M4, number of high-dose procedures appeared positively
associated with AML risk (P trend¼0.03 based on interview data,
Table 3), as did total dose from radiographic procedures (Table 4).
However, this relationship appears to result from M4 controls
being unusual in that they had relatively few high-dose procedures
and low total exposure compared with all controls combined.
There were no discrepancies among controls by FAB subtype in
distributions of factors (age, sex, ethnicity, and SES) that might be
associated with access to or willingness to seek medical care (data
not shown). There were no other apparent dose-response relation-
ships suggesting increased risk, either for all pairs combined or for
specific FAB subtypes. PAR based on medical records was 5%
(95% CI: 3%, 11%) for all pairs combined. In multivariable
analyses of cumulative dose during three different periods of age at
exposure – 0–39, 40–54, and 55þ years – no particular age period
was associated with significantly increased risk. Analyses based on
medical records that retained all matched pairs but included an
indicator covariate for missing exposure data, produced results
similar to the primary analyses (data not shown).
DISCUSSION
We observed no apparent relationship between radiation exposure
from diagnostic imaging procedures and adult AML risk,
confirming the lack of association reported from earlier epide-
miological studies (Linos et al, 1980; Boice Jr et al, 1991; Zheng
et al, 1993; Yuasa et al, 1997). In fact, there have been no prior
reports showing convincing evidence of such an association.
Stewart et al (1962) reported an association between trunk x-rays
and myeloid and monocytic leukaemia, but 11 years later
attributed it to diagnostic procedures related to the leukaemia
disease process. A more recent study from Japan suggested that an
association between AML risk and conditions that may lead to
increased x-ray exposure (e.g., bone fracture) links AML risk to
x-ray exposure (Wakabayashi et al, 1994), but data on x-ray
exposure were not collected and thus this hypothesis could not be
tested directly.
The lack of evidence from epidemiological studies of an
association between adult AML and diagnostic radiography
supports the BEIR VII model for leukaemia, which predicts a
relative risk of 1.017 per 0.01 Sv (equivalent to 10 mGy) exposure
for a male over 30-years old, 10 years after exposure (Board on
Radiation Effects Research, 2006). This effect size would be very
difficult to detect in an epidemiological study of diagnostic
Table 3 Risk analysis of number of most frequently reported diagnostic imaging procedures in the 2–10 years before diagnosis, adjusted for SES
a
Data from medical records Data from interview
High dose
b Low dose
b High dose
b Low dose
b
FAB
group
#
Exams
#
Ca
#
Co OR (95% CI)
P
trend
c
#
Ca
#
Co OR (95% CI)
P
trend
c
#
Ca
#
Co OR (95% CI)
P
trend
c
#
Ca
#
Co OR (95% CI)
P
trend
c
All
d 0 162 146 1.0 0.74 95 88 1.0 0.11 212 199 1.0 0.54 104 80 1.0 0.41
1–4 98 120 0.7 (0.5, 1.0) 136 116 1.0 (0.7, 1.5) 117 140 0.8 (0.6, 1.1) 164 168 0.7 (0.5, 1.1)
X5 19 13 1.2 (0.6, 2.4) 48 75 0.5 (0.3, 0.9) 15 5 2.7 (1.0, 7.5) 76 96 0.6 (0.4, 1.0)
M1 0 34 31 1.0 0.21 19 13 1.0 0.03 41 41 1.0 0.80 24 14 1.0 0.52
1–4 19 19 0.9 (0.4, 2.0) 28 25 0.7 (0.3, 1.8) 26 26 1.0 (0.5, 2.0) 25 34 0.4 (0.2, 1.0)
X5 2 5 0.4 (0.1, 2.1) 8 17 0.3 (0.1, 1.0) 0 0 — — 18 19 0.5 (0.2, 1.4)
M2 0 42 45 1.0 0.44 25 26 1.0 0.20 65 55 1.0 0.57 29 25 1.0 0.19
1–4 32 31 1.0 (0.5, 2.1) 42 28 2.0 (0.9, 4.3) 29 41 0.6 (0.3, 1.2) 52 45 1.2 (0.6, 2.3)
X5 5 3 1.6 (0.4, 6.8) 12 25 0.4 (0.1, 1.2) 5 3 1.4 (0.3, 6.2) 18 29 0.7 (0.3, 1.6)
M3 0 18 10 1.0 0.49 10 5 1.0 0.23 24 17 1.0 0.82 8 8 1.0 0.32
1–4 5 16 0.2 (0.0, 0.8) 10 15 0.4 (0.1, 1.6) 8 16 0.2 (0.0, 0.9) 15 21 0.6 (0.2, 1.9)
X5 4 1 1.7 (0.2,19.3) 7 7 0.6 (0.1, 2.9) 1 0 — — 10 4 2.0 (0.6, 7.3)
M4
e 0 25 26 1.0 0.13 14 21 1.0 0.57 37 49 1.0 0.03 20 14 1.0 0.61
1–4 23 26 0.8 (0.4, 1.8) 27 19 2.2 (0.8, 5.9) 32 23 1.9 (0.9, 4.1) 37 38 0.6 (0.3, 1.5)
X5 6 2 2.5 (0.5,13.2) 13 14 1.5 (0.5, 4.5) 4 1 4.5 (0.5,41.4) 16 21 0.5 (0.2, 1.5)
M5
f 0 11 12 1.0 1.00 6 7 1.0 0.10 11 12 1.0 0.67 2 6 1.0 0.11
1–4 6 7 0.5 (0.1, 2.7) 9 8 0.6 (0.1, 3.3) 8 9 0.8 (0.2, 2.7) 17 9 2.7 (0.3,27.0)
X5 2 0 — — 4 4 0.3 (0.0, 3.2) 2 0 — — 2 6 0.4 1(0.0,12.6)
Abbreviations: Ca¼cases; CI¼confidence interval; Co¼controls; FAB¼French–American–British; OR¼odds ratio; SES¼socioeconomic status.
aExcludes pairs in which
either the case or control had prior radiation therapy and/or chemotherapy for cancer.
bCutoff between ‘high’ and ‘low’ dose to active bone marrow was 1mGy.
cActual number
of procedures as a continuous variable.
dIncludes 51 case-control pairs with unknown FAB subtype.
eExcludes cases with FAB subtype M4eo.
fIncludes cases with FAB subtypes
M5A and M5B.
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required, the exposure typically received from these types of
procedures (10mGy¼about 200 chest x-rays), and the rarity
of AML.
It is worth mentioning that the BEIR VII analysis excluded
leukaemia cases that occurred during the first 5 years after atomic
bomb exposure, yet several studies of medically exposed cohorts
have reported highest relative risks in the 1–5 years after exposure
(Board on Radiation Effects Research, 2006). Thus, it is possible
that limitations in our study prevented us from detecting increased
AML risk from recent exposure. For example, a relatively small
proportion (57%) of eligible cases were able to participate in the
study; this is an inherent problem in any epidemiological study of
AML, which must rely on the case-control design due to the low
incidence of disease. Because median survival after AML diagnosis
is measured in months vs years, and because our median time to
interview was 7 months, non-participation in our study was largely
due to death (and lack of an available proxy). If non-participating
cases had more exposure in the few years just before diagnosis –
for example, if radiation exposure causes a more rapidly fatal form
of AML – our study would have missed this potential causal effect.
Exposure misclassification can result in biased estimates of
disease risk. All indicators we were able to examine (e.g.,
comparison of interview with medical record data) suggested that
misclassification in our study was either non-differential, which
tends to bias risk estimates towards the null, or was present in a
way that would bias towards the null; for example, proxy
respondents underreporting to a greater degree than non-proxies
(Pogoda and Preston-Martin, 2002).
Estimates of US radiographic doses are uncertain because not all
relevant details, such as number of retakes, were considered
(Preston-Martin and Pogoda, 2003). Failure to consider retake rate
consistently underestimates per-procedure dose to the patient. We
conducted a telephone survey of Los Angeles County facilities that
provide diagnostic radiography (n¼174) to ascertain retake rates
for common procedures and found that mean retake rate for the
most common procedures ranged from 5.5% (range¼1.2–18.2%)
for upper gastrointestinal series to 24.7% (range¼1–100%) for
routine chest examinations. Several common high-dose proce-
dures had relatively high average retake rates, for example,
lumbosacral spine examinations (mean 16.2%, range¼4–53%).
Our dose estimates are also likely to consistently underestimate
actual doses delivered because they are derived from dosimetry
surveys from the US and other Western countries, all of which
assume use of ideal radiographic conditions (Preston-Martin and
Pogoda, 2003).
In summary, our study has not provided convincing evidence
supporting an association between diagnostic radiography and
adult AML risk. Although such an association would not be
expected based on the BEIR VII report, there remains uncertainty
regarding the first 5 years after exposure, and there are enough
limitations to a case-control study such as ours that it is not
possible to conclude that such an increased risk does not exist.
Further, it is important to note that radiation exposure from
diagnostic imaging procedures increases with improved image
quality due to improved equipment (Smith-Bindman, 2010) which,
coupled with the dramatic increased use of imaging by medical
practitioners since our study was conducted (Hillman and
Goldsmith, 2010), suggests that our subjects were exposed to
lower doses of radiation from diagnostic procedures than they
would have been in the current healthcare environment.
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Table 4 Risk analysis of total estimated bone marrow dose from diagnostic imaging procedures in the 2–10 years before diagnosis, adjusted for SES
a
Data from medical records Data from interview
FAB
group
Total estimated dose
(mGy)
b # Ca # Co OR (95% CI) P trend
c # Ca # Co OR (95% CI) P trend
c
All
d p1000 234 236 1.0 0.28 295 290 1.0 0.70
1001–2000 22 30 0.7 (0.4, 1.3) 31 46 0.6 (0.4, 1.0)
42000 23 13 1.6 (0.8, 3.2) 18 8 2.5 (1.0, 6.0)
M1 p1000 49 48 1.0 0.76 58 56 1.0 0.95
1001–2000 4 3 1.3 (0.3, 5.9) 6 11 0.6 (0.2, 1.7)
42000 2 4 0.5 (0.1, 2.9) 3 0 —
M2 p1000 65 66 1.0 0.54 89 84 1.0 0.46
1001–2000 6 10 0.7 (0.2, 2.1) 7 10 0.6 (0.2, 1.8)
42000 8 3 2.2 (0.6, 9.0) 3 5 0.6 (0.1, 2.6)
M3 p1000 22 24 1.0 0.27 27 31 1.0 0.18
1001–2000 2 3 0.6 (0.1, 3.8) 1 2 0.5 (0.0, 5.5)
42000 3 0 — 5 0 — —
M4
e p1000 39 48 1.0 0.10 57 64 1.0 0.054
1001–2000 8 5 2.0 (0.5, 8.1) 12 8 1.4 (0.5, 4.0)
42000 7 1 6.7 (0.8, 55.4) 4 1 4.7 (0.5,43.1)
M5
f p1000 17 16 1.0 0.63 18 19 1.0 0.96
1001–2000 0 2 0.0 (0.0, —) 1 2 0.6 (0.1, 7.7)
42000 2 1 1.9 (0.1, 53.1) 2 0 —
Abbreviations: Ca¼cases; CI¼confidence interval; Co¼control; FAB¼French-American-British; OR¼odds ratio; SES¼socioeconomic status.
aExcludes pairs in which either
the case or control had prior radiation therapy and/or chemotherapy for cancer.
bDose is likely to be consistently underestimated (see text).
cTotal dose as a continuous variable.
dIncludes 51 case-control pairs with unknown FAB subtype.
eExcludes cases with FAB subtype M4eo.
fIncludes cases with FAB subtypes M5A and M5B.
Radiography and risk of AML
JM Pogoda et al
1485
British Journal of Cancer (2011) 104(9), 1482–1486 & 2011 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yES07048. Cases were identified by the Cancer Surveillance Program
with support from SEER contract NO1-CN-25403 of the Division of
Cancer Prevention and Control, National Cancer Institute,
National Institutes of Health, Department of Health and Human
Services and contracts 050 (C-J)-8709 from the State of California
Department of Health Services.
We thank Maria Paul, Rosemarie Hanish, Kristina Paoff,
and Jennifer Martin Borja for help with interviewing and
study coordination. In addition we are grateful to the AML
patients, their family members and their neighbors who partici-
pated. Without their support this study would not have been
possible.
REFERENCES
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR,
Sultan C (1976) Proposals for the classification of the acute leukaemias.
French-American-British (FAB) co-operative group. Br J Haematol 33:
451–458
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR,
Sultan C (1985a) Criteria for the diagnosis of acute leukemia of
megakaryocyte lineage (M7). A report of the French-American-British
Cooperative Group. Ann Intern Med 103: 460–462
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR,
Sultan C (1985b) Proposed revised criteria for the classification of acute
myeloid leukemia. A report of the French-American-British Cooperative
Group. Ann Intern Med 103: 620–625
Board on Radiation Effects Research (2006) Health Risks From Exposure to
Low Levels of Ionizing Radiation: BEIR VII Phase 2. National Academy of
Sciences: Washington DC
Boice Jr JD, Morin MM, Glass AG, Friedman GD, Stovall M,
Hoover RN, Fraumeni Jr JF (1991) Diagnostic x-ray procedures
and risk of leukemia, lymphoma, and multiple myeloma. JAMA 265:
1290–1294
Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume
I - the analysis of case-control studies. IARC Sci Publ 32: 5–338
Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C (1985) Estimating the
population attributable risk for multiple risk factors using case-control
data. Am J Epidemiol 122: 904–914
Darby SC, Doll R, Gill SK, Smith PG (1987) Long term mortality after a
single treatment course with X-rays in patients treated for ankylosing
spondylitis. Br J Cancer 55: 179–190
Hillman BJ, Goldsmith JC (2010) The uncritical use of high-tech medical
imaging. N Engl J Med 363: 4–6
Hollingshead A (1957) A two-factor index of social position. A. Hollings-
head: New Haven, CT
Huberman M, Langholz B (1999) Application of the missing-indicator
method in matched case-control studies with incomplete data. Am J
Epidemiol 150: 1340–1345
Linos A, Gray JE, Orvis AL, Kyle RA, O’Fallon WM, Kurland LT (1980)
Low-dose radiation and leukemia. N Engl J Med 302: 1101–1105
Pogoda JM, Preston-Martin S (2002) Radiation exposure from diagnostic
imaging: agreement between self-report and medical records. Health
Phys 83: 907–917
Pogoda JM, Preston-Martin S, Nichols PW, Ross RK (2002) Smoking and
risk of acute myeloid leukemia: results from a Los Angeles County
case-control study. Am J Epidemiol 155: 546–553
Preston DL, Kato K, Kopecky KJ, Fugita S (1987) Life Span Study Report 10.
Part Cancer Mortality among A-bomb Survivors in Hiroshima and
Nagasaki, 1950–1982. Technical Report RERF TR 1-86. Hiroshima,
Radiation Effects Research Foundation
Preston-Martin S, Paganini-Hill A, Henderson BE, Pike MC, Wood C (1980)
Case-control study of intracranial meningiomas in women in Los
Angeles County, California. J Natl Cancer Inst 65: 67–73
Preston-Martin S, Pogoda JM (2003) Estimation of radiographic doses in a
case-control study of acute myelogenous leukemia. Health Phys 84: 245–259
Sandler DP, Shore DL, Anderson JR, Davey FR, Arthur D, Mayer RJ, Silver
RT, Weiss RB, Moore JO, Schiffer CA (1993) Cigarette smoking and risk
of acute : associations with morphology and cytogenetic abnormalities in
bone marrow. J Natl Cancer Inst 85: 1994–2003
Smith-Bindman R (2010) Is computed tomography safe? N Engl J Med
363: 1–4
Stewart A, Pennybacker W, Barber R (1962) Adult leukaemias and
diagnostic x rays. Brit Med J 2: 882–890
Wakabayashi I, Sakamoto K, Masui H, Yoshimoto S, Kanamaru A,
Kakishita E, Hara H, Shimo-oku M, Nagai K, Shimo-oka M (1994) A
case-control study on risk factors for leukemia in a district of Japan.
Intern Med 33: 198–203
Yuasa H, Hamajima N, Ueda R, Ohno R, Asou N, Utsunomiya A, Ogura M,
Takigawa N, Ueda T, Hiraoka A, Matsuda S, Kuraishi Y, Nishikawa K,
Uike N, Takeshita A, Takemoto Y, Shimazaki C, Sakamaki H, Ino T,
Matsushima T, Kuriyama K, Hirai H, Naoe T, Tsubaki K, Takahashi I
(1997) Case-control study of leukemia and diagnostic radiation
exposure. Int J Hematol 65: 251–261
Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni Jr JF (1993) Prior
medical conditions and the risk of adult leukemia in Shanghai, People’s
Republic of China. Cancer Causes Control 4: 361–368
Radiography and risk of AML
JM Pogoda et al
1486
British Journal of Cancer (2011) 104(9), 1482–1486 & 2011 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y